News | July 11, 2025
Bayer submits EU application for Gadoquatrane MRI contrast agent
It is intended for contrast enhancement in MRI scans
It is intended for contrast enhancement in MRI scans
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
EBITDA before special items decreases to €4.08 billion (7.4%)
Bayer expects 2025 to be the most difficult year of its turnaround
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Subscribe To Our Newsletter & Stay Updated
